Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + domvanalimab + chemotherapy versus pembrolizumab + chemotherapy in first-line metastatic NSCLC
NL-OMON53866Phase 3Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zimberelimab, domvanalimab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Progression-free survival and Overall survival. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53866.